- Home
- PLAY vs GERN Comparison
PLAY vs GERN Comparison
Compare PLAY & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLAY
- GERN
- Stock Information
- Founded
- PLAY 1982
- GERN 1990
- Country
- PLAY United States
- GERN United States
- Employees
- PLAY N/A
- GERN N/A
- Industry
- PLAY Restaurants
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- PLAY Consumer Discretionary
- GERN Health Care
- Exchange
- PLAY Nasdaq
- GERN Nasdaq
- Market Cap
- PLAY 1.1B
- GERN 974.5M
- IPO Year
- PLAY 1995
- GERN 1996
- Fundamental
- Price
- PLAY $34.03
- GERN $1.43
- Analyst Decision
- PLAY Hold
- GERN Buy
- Analyst Count
- PLAY 8
- GERN 7
- Target Price
- PLAY $31.83
- GERN $4.17
- AVG Volume (30 Days)
- PLAY 1.6M
- GERN 9.7M
- Earning Date
- PLAY 06-10-2025
- GERN 08-07-2025
- Dividend Yield
- PLAY N/A
- GERN N/A
- EPS Growth
- PLAY N/A
- GERN N/A
- EPS
- PLAY 1.02
- GERN N/A
- Revenue
- PLAY $2,112,300,000.00
- GERN $116,293,000.00
- Revenue This Year
- PLAY $3.62
- GERN $160.12
- Revenue Next Year
- PLAY $6.33
- GERN $55.01
- P/E Ratio
- PLAY $34.01
- GERN N/A
- Revenue Growth
- PLAY N/A
- GERN 22264.04
- 52 Week Low
- PLAY $15.08
- GERN $1.17
- 52 Week High
- PLAY $43.73
- GERN $5.06
- Technical
- Relative Strength Index (RSI)
- PLAY 73.82
- GERN 46.80
- Support Level
- PLAY $29.55
- GERN $1.34
- Resistance Level
- PLAY $32.02
- GERN $1.57
- Average True Range (ATR)
- PLAY 1.61
- GERN 0.10
- MACD
- PLAY 0.01
- GERN -0.02
- Stochastic Oscillator
- PLAY 83.61
- GERN 37.50
About PLAY Dave & Buster's Entertainment Inc.
Dave & Buster's Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports. Each store offers a full menu of entries and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. It derives maximum revenue from Entertainment.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.